By Josh Beckerman
Shares of Claritev rose after it reported revenue in the fourth quarter on par with its previously issued guidance.
The stock increased 18%, to $23.13, midday Wednesday and is up about 57% this year.
Claritev said it had fourth-quarter revenue of $232.1 million, down 4.9% from a year earlier but slightly up from the third-quarter figure of $230.5 million. The company guided in November for fourth-quarter results similar to the third quarter.
The company, which changed its name from MultiPlan, said it would trade under a new ticker symbol, CTEV, on Friday. The company's operations include analytics-based services that detect medical claims over-charges and recommend reimbursement amounts for out-of-network costs, and operation of preferred provider networks.
Net loss was $138 million, compared with a loss of $31.4 million a year earlier, partly due to an impairment charge stemming from the name change.
Claritev expects 2025 revenue between a 2% decline and flat compared with 2024.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 26, 2025 14:05 ET (19:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。